• Biovica signed a master services agreement with a US biotechnology company to supply DiviTum TKa testing services for oncology drug development.
• Framework covers multiple programs targeting cell-cycle pathways where TKa measurements may be used; projects will be launched through separate work orders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.